eMC Medicine Guides  
The electronic Medicines Compendium (eMC) contains information about UK licensed medicines.
go to eMC homepage
Search for:  
  Advanced Search

CSL Behring UK Limited
Hayworth House, Market Place, Haywards Heath, West Sussex, RH16 1DB, UK
Telephone: +44 (0)1444 447 400
Fax: +44 (0)1444 447 403
WWW: http://www.cslbehring.co.uk
Medical Information Direct Line: +44 (0)1444 447 405
Medical Information e-mail: medinfo@cslbehring.com
Customer Care direct line: +44 (0)1444 447 402
Out of Hours contact: +44 (0)1444 447 405

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Patient Information Leaflet last updated on the eMC: 01/09/2011
PIL Helixate NexGen 500 IU

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 01/09/2011 and displayed until Current
Reasons for adding or updating:
  • Change to Marketing Authorisation Holder
Updated on 20/01/2011 and displayed until 01/09/2011
Reasons for adding or updating:
  • Change to storage instructions
Updated on 07/01/2011 and displayed until 20/01/2011
Reasons for adding or updating:
  • Change to Further Information section
  • Change to storage instructions
Updated on 16/09/2010 and displayed until 07/01/2011
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to Further Information section
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to instructions about overdose
  • Change to storage instructions
Updated on 26/04/2010 and displayed until 16/09/2010
Reasons for adding or updating:
  • Change/addition of instructions for reconstitution and/ or administration
  • Change to Further Information section
Updated on 11/09/2009 and displayed until 26/04/2010
Reasons for adding or updating:
  • Change to side-effects
Updated on 19/06/2008 and displayed until 11/09/2009
Reasons for adding or updating:
  • Transfer to upgraded management system
Updated on 21/12/2007 and displayed until 19/06/2008
Reasons for adding or updating:
  • Change to side-effects
  • Change to Further Information section
  • Change to name of manufacturer
  • Change to date of revision
Updated on 24/08/2007 and displayed until 21/12/2007
Reasons for adding or updating:
  • Change to date of revision
Updated on 28/03/2007 and displayed until 24/08/2007
Reasons for adding or updating:
  • Change to, or new, use for medicine
Updated on 22/02/2007 and displayed until 28/03/2007
Reasons for adding or updating:
  • Change to, or new, use for medicine
Updated on 31/10/2006 and displayed until 22/02/2007
Reasons for adding or updating:
  • Change to date of revision
  • Change to storage instructions
Updated on 26/06/2006 and displayed until 31/10/2006
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 28/05/2003 and displayed until 26/06/2006
Reasons for adding or updating:
  • PIL Company name change or merger
  • Improved Electronic Presentation
Updated on 21/05/2003 and displayed until 28/05/2003
Reasons for adding or updating:
  • Update to PIL
Updated on 30/08/2002 and displayed until 21/05/2003
Reasons for adding or updating:
  • Update to PIL
Updated on 22/10/2001 and displayed until 30/08/2002
Reasons for adding or updating:
  • Update to PIL
Updated on 08/10/2001 and displayed until 22/10/2001
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
  octocog alfa